|
Takada et al. [91]
|
IHC (RTJ2)
|
met-HER2+ BCA (n = 29), TPD
|
↓ Low HER3 expression was associated with shortened PFS
|
|
Adamczyk et al. [25]
|
IHC (SP71)
|
HER2+ BCA (n = 97), Adj.T
|
↑ High HER3 expression (only with concurrent PTEN negativity) was associated with shorten MFS
|
|
Duchnowska et al. [44]
|
VeraTag assay
|
HER2+ BCA (n = 189), Adj.T
|
- No correlation between HER3 expression and OS in advanced stage HER2 + BCA
|
|
Nishimura et al. [54]
|
VeraTag assay
|
met-HER2+ BCA (n = 47), T
|
- HER3 expression did not has any influence on PFS in trastuzumab-refractory advanced HER2 + BCA
|
|
Koutras et al. [39]
|
qRT-PCR
|
BCA (n = 663, HER2 + BCA n = 143)
|
↓ Low HER3 mRNA (only with concurrently high EGFR, high HER2, low HER4 mRNA) was associated with worse DFS
|
|
Baselga et al. [38]
|
qRT-PCR*, IHC** (DAK-H3-IC)
|
HER2+ BCA (n = 740*/497**), Adj.T
|
↓ High HER3 mRNA was associated with better prognosis in metastatic HER2 + BCA
|
|
Berghoff et al. [16]
|
IHC (DAK-H3-IC)
|
met-BCA (n = 110, met-HER2 + BCA n = 34)
|
↑ High HER3 expression was associated with shorter OS in initially metastatic HER2 + BCA subgroup
|
|
Park et al. [31]
|
IHC (DAK-H3-IC)
|
met-HER2+ BCA (n = 125), T
|
↑ High HER3 expression was associated with worse PFS in initially metastatic HER2 + BCA
|
|
Bae et al. [26]
|
IHC (DAK-H3-IC)
|
HR-BCA (n = 886, HER2 + BCA n = 221)
|
↑ High HER3 expression was associated with poorer DFS in HER2 + BCA subgroup and poorer DFS and OS in TNBC
|
|
Czopek et al. [48]
|
IHC (DAK-H3-IC)
|
HER2+ BCA (n = 35)
|
- No correlation between HER3 expression and DFS or OS
|
|
Lipton et al. [29]
|
VeraTag assay
|
met-HER2+ BCA (n = 89), T
|
↑ High HER3 expression was associated with shorter PFS in initially metastatic HER2 + BCA
|
|
Gori et al. [41]
|
IHC (RTJ1)
|
met-HER2+ BCA (n = 61), T
|
- HER3 was not significantly associated with clinical outcome in initially metastatic HER2 + BCA
|
|
Han et al. [37]
|
VeraTag assay
|
met-HER2+ BCA (n = 50), T
|
↓ High HER3 expression was related to longer TTP in advanced HER2 + BCA
|
|
Larsen et al. [43]
|
IHC (DAK-H3-IC)
|
ER+ BCA (n = 1062)
|
- HER3 expression did not shown any association to DFS
|
|
Chiu et al. [27]
|
IHC (Ab-10 pAb)
|
BCA (n = 3123)
|
↑ High HER3 expression was associated with decreased BCSS
|
|
Yonemori et al. [45]
|
IHC (DAK-H3-IC)
|
HER2+ BCA (n = 44), neoAdj.T
|
- HER3 expression did not significantly correlate with pCR
|
|
Giltnane et al. [28]
|
AQUA
|
BCA (n = 550)
|
↑ High HER3 expression was associated with decreased survival
|
|
Haas et al. [42]
|
IHC (SGP1)
|
HER2- BCA (n = 171)
|
- No prognostic value for HER3
|
|
Sassen et al. [50]
|
IHC (5A12), FISH
|
BCA (n = 173)
|
- No prognostic value for HER3 expression, HER3 gene amplification was related to decreased DFS
|
|
Giuliani et al. [52]
|
IHC (RTJ1)
|
met-HER2+ BCA (n = 103), T
|
- No prognostic value for HER3
|
|
Lee et al. [36]
|
IHC (pAb)
|
BCA (n = 378)
|
↓ High HER3 expression correlated with longer DFS
|
|
Bianchi et al. [53]
|
IHC (RTJ1)
|
BCA (n = 145)
|
- No prognostic value for HER3 expression singly, but high co-expression of HER2/3/4 predicted worse prognosis
|
|
Fuchs et al. [34]
|
IHC (C-17 pAb)
|
BCA (n = 48)
|
↑ High HER3 expression singly and in co-expression with high HER1 and HER2 was associated with poor prognosis
|
|
Robinson et al. [32]
|
IHC (polyclonal)
|
met-HER2+ BCA (n = 104), T
|
↑ High HER3 expression was associated with worse OS
|
|
Wiseman et al. [33]
|
IHC (2-18C9)
|
BCA (n = 242)
|
↑ High HER3 expression independently and with high HER1 and/or HER2 was associated with decreased DSS
|
|
Abd El-Rehim et al. [15]
|
IHC (RTJ1)
|
BCA (n = 1499)
|
- No prognostic value for HER3 singly, but in co-expression with high HER2 predicted unfavorable DFS and OS
|
|
Smith et al. [49]
|
IHC
|
met-HER2+ BCA (n = 77), T
|
- No prognostic value for HER3
|
|
Bièche et al. [35]
|
qRT-PCR
|
BCA (n = 130)
|
↑ High HER3 mRNA was associated with shorten RFS
|
|
Witton et al. [30]
|
IHC (H3.105.5)
|
BCA (n = 220)
|
↑ High HER3 expression was associated with reduced BCSS survival
|
|
Suo et al. [47]
|
IHC (sc-415), RT-PCR
|
BCA (n = 100)
|
- High HER3 expression was predictive for reduced DFS or BCSS only in co-overexpression with HER2 or HER1 + HER2
|
|
Pawlowski et al. [40]
|
qRT-PCR
|
BCA (n = 365)
|
↓ Elevated HER3 mRNA expression was associated with a better prognosis in terms of OS, but did not relate to RFS
|
|
Travis et al. [46]
|
IHC (RTJ1)
|
BCA (n = 346), met-BCA (n = 145)
|
- No prognostic value for HER3 expression neither in primary nor metastatic breast cancer
|
|
Lemoine et al. [51]
|
IHC (49.3 pAb)
|
BCA (n = 195)
|
- No demonstrable relationship between HER3 expression and survival
|
